Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo

Melanoma Research

Volumn 18, Issue 6, 2008, Pages 420-430

  Triozzi, Pierre L ^a,b   Aldrich, Wayne ^a   Dombos, Christopher ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

KIT; O6 methylguanine DNA methyltransferase; Platelet derived growth factor; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; CD11B ANTIGEN; IMATINIB; TEMOZOLOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL STIMULATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG MEGADOSE; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MACROPHAGE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; STROMA; TISSUE PRESSURE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR XENOGRAFT; UVEA MELANOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; HUMANS; MELANOMA; MICE; PIPERAZINES; PYRIMIDINES; UVEAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 56849100768     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3283194118     Document Type: Article

References (49)

1. Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology 2003; 110:962-965.
2. Singh AD, Borden EC. Metastatic uveal melanoma. Ophthalmol Clin North Am 2005; 18:143-150.
3. Capdeville R, Silberman S. Imatinib: a targeted clinical drug development. Semin Hematol 2003; 40:15-20.
4. Pache M, Glatz K, Bosch D, Dirnhofer S, Mirlacher M, Simon R, et al. Sequence analysis and high-throughput immunohistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays. Virchows Arch 2003; 443:741-744.
5. All-Ericsson C, Girnita L, Muller-Brunotte A, Brodin B, Seregard S, Ostman A, et al. Kit-dependent growth of uveal melanoma cells: a potential therapeutic target? Invest Ophthalmol Vis Sci 2004; 45:2075-2082.
6. Pereira PR, Odashiro AN, Marshall JC, Correa ZM, Belfort R Jr, Burnier MN Jr. The role of c-kit and imatinib mesylate in uveal melanoma. J Carcinog 2005; 4:19.
7. Lefevre G, Glotin AL, Calipel A, Mouriaux F, Tran T, Kherrouche Z, et al. Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis. J Biol Chem 2004; 279:31769- 31779.
8. Fiorentini G, Rossi S, Lanzanova G, Biancalani M, Palomba A, Bernardeschi P, et al. Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial. J Exp Clin Cancer Res 2003; 22 (4 Suppl):17-20.
9. Knight LA, Di Nicolantonio F, Whitehouse PA, Mercer SJ, Sharma S, Glaysher S, et al. The effect of imatinib mesylate (Glivec) on human tumor-derived cells. Anticancer Drugs 2006; 17:649-655.
10. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004; 4:806-813.
11. Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, Heldin CH, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001; 61:2929-2934.
12. Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002; 62:5476-5484.
13. Pietras K, Stumm M, Hubert M, Buchdunger E, Rubin K, Heldin CH, et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 2003; 9:3779-3787.
14. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-166.
15. Wiig H, Tveit E, Hultborn R, Reed RK, Weiss L. Interstitial fluid pressure in DMBA-induced rat mammary tumors. Scand J Clin Lab Invest 1982; 42:159-1642.
16. Chou T-C, Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 1983; 4:450-454.
17. Seftor EA, Meltzer PS, Kirschmann DA, Pe'er J, Maniotis AJ, Trent JM, et al. Molecular determinants of human uveal melanoma invasion and metastasis. Clin Exp Metastasis 2002; 19:233-246.
18. Daniels KJ, Boldt HC, Martin JA, Gardner LM, Meyer M, Folberg R. Expression of type VI collagen in uveal melanoma: its role in pattern formation and tumor progression. Lab Invest 1996; 75:55-66.
19. Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci U S A 2001; 98:8018-8023.
20. Passagne I, Evrard A, Winum JY, Depeille P, Cuq P, Montera JL, et al. Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNA-methyltransferase expression. J Pharmacol Exp Ther 2003; 307:816-823.
21. Nikolova Z, Peng B, Hubert M, Sieberling M, Keller U, Ho YY, et al. Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. Cancer Chemother Pharmacol 2004; 53:433-438.
22. Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 2004; 96:46-55.
23. Litz J, Krystal GW. Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1 alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells. Mol Cancer Ther 2006; 5:1415-1422.
24. Triozzi PL, Aldrich W, Allen KO, Lima J, Shaw DR, Strong TV. Antitumor activity of the intratumoral injection of fowlpox vectors expressing a triad of costimulatory molecules and granulocyte/macrophage colony stimulating factor in mesothelioma. Int J Cancer 2005; 113:406-414.
25. Mouriaux F, Kherrouche Z, Maurage CA, Demailly FX, Labalette P, Saule S. Expression of the c-kit receptor in choroidal melanomas. Melanoma Res 2003; 13:161-166.
26. Montone KT, van Belle P, Elenitsas R, Elder DE. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol 1991; 10:939-944.
27. Ijland SA, Jager MJ, Heijdra BM, Westphal JR, Peek R. Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines. Melanoma Res 1999; 9:445-450.
28. Shen SS, Zhang PS, Eton O, Prieto VG. Analysis of protein tyrosine kinase expression in melanocyte lesions by tissue array. J Cutan Pathol 2003; 30:539-547.
29. Uziel O, Fenig E, Nordenberg J, Beery E, Reshef H, Sandbank J, et al. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer 2005; 92:1881-1891.
30. Notting IC, Missotten GS, Sijmons B, Boonman ZF, Keunen JE, van der Pluijm G. Angiogenic profile of uveal melanoma. Curr Eye Res 2006; 31:775-785.
31. Berube M, Deschambeault A, Boucher M, Germain L, Petitclerc E, Guerin SL. MMP-2 expression in uveal melanoma: differential activation status dictated by the cellular environment. Mol Vis 2005; 11:1101-1111.
32. Mueller L, Goumas FA, Himpel S, Brilloff S, Rogiers X, Broering DC. Imatinib mesylate inhibits proliferation and modulates cytokine expression of human cancer-associated stromal fibroblasts from colorectal metastases. Cancer Lett 2007; 250:329-338.
33. Myatt N, Cree IA, Kurbacher CM, Foss AJ, Hungerford JL, Plowman PN. The ex vivo chemosensitivity profile of choroidal melanoma. Anticancer Drugs 1997; 8:756-762.
34. Darkes MJM, Plosker GL, Jarvis B. Temozolomide. A review of its use in the treatment of malignant gliomas, malignant melanoma and other advanced cancer. Am J Cancer 2002; 1:55-80.
35. McGary EC, Onn A, Mills L, Heimberger A, Eton O, Thomas GW, et al. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. J Invest Dermatol 2004; 122:400-405.
36. Redondo P, Lloret P, Andreu EJ, Inoges S. Imatinib mesylate in cutaneous melanoma. J Invest Dermatol 2004; 123:1208-1209.
37. http://clinicaltrials.gov.
38. Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006; 106:2005-2011.
39. Ugurel S, Hildenbrand R, Zimpfer A, La Rosee P, Paschka P, Sucker A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma Br J Cancer 2005; 92:1398-1405.
40. Willett CG, Boucher Y, di Tomaso E, Duda DG, Chung DC, Sahani DV, et al. Direct evidence that the anti-VEGF antibody bevacizumab has anti-vascular effects in human rectal cancer. Nat Med 2004; 10:145-147.
41. Baranowska-Kortylewicz J, Abe M, Pietras K, Kortylewicz ZP, Kunzaki T, Nearman J, et al. Effect of platelet-derived growth factor receptor-B inhibition with STI571 on radioimmunotherapy. Cancer Res 2005; 65:7824-7831.
42. Lin MI, Sessa WC. Antiangiogenic therapy: creating a unique 'window' of opportunity. Cancer Cell 2004; 6:529-531.
43. Vlahovic G, Rabbani ZN, Herndon JE II, Dewhirst MW, Vujaskovic Z. Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. Br J Cancer 2006; 95:1013-1019.
44. Salnikov AV, Roswall P, Sundberg C, Gardner H, Heldin NE, Rubin K. Inhibition of TGF-beta modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma. Lab Invest 2005; 85:512-521.
45. Inaba T, Shimano H, Gotoda T, Harada K, Shimada M, Ohsuga J, et al. Expression of platelet-derived growth factor β receptor on human monocyte-derived macrophages and effects of platelet-derived growth factor BB dimer on the cellular function. J Biol Chem 1993; 268:24353-24360.
46. Dewar AL, Domaschenz RM, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. Leukemia 2003; 17:1713-1721.
47. Wang H, Cheng F, Cuenca A, Homa P, Zheng Z, Bhalla K, et al. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood 2005; 105:1135-1143.
48. Mäkitie T, Summanen P, Tarkkanen A, Kivelä T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci 2001; 42:1414-1421.
49. + myeloid cells correlates with the failure to prevent tumor growth in the anterior chamber of the eye. J Immunol 2006; 177:1599-1608.